Published in Clin Exp Immunol on December 01, 1992
Pathogenesis of human immunodeficiency virus infection. Microbiol Rev (1993) 5.88
Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy. J Infect Dis (2010) 2.98
Temporal and anatomic relationship between virus replication and cytokine gene expression after vaginal simian immunodeficiency virus infection. J Virol (2005) 2.01
T cell activation and disease severity in HIV infection. Clin Exp Immunol (1993) 1.53
Selective increase of activation antigens HLA-DR and CD38 on CD4+ CD45RO+ T lymphocytes during HIV-1 infection. Clin Exp Immunol (1994) 1.46
T cell activation, apoptosis and cytokine dysregulation in the (co)pathogenesis of HIV and pulmonary tuberculosis (TB). Clin Exp Immunol (2000) 1.17
Immune exhaustion occurs concomitantly with immune activation and decrease in regulatory T cells in viremic chronically HIV-1-infected patients. J Acquir Immune Defic Syndr (2010) 1.16
Impaired antibody response to influenza vaccine in HIV-infected and uninfected aging women is associated with immune activation and inflammation. PLoS One (2013) 1.06
Changes in natural immunity during the course of HIV-1 infection. Clin Exp Immunol (1993) 1.02
Expression of CD28 and CD38 by CD8+ T lymphocytes in HIV-1 infection correlates with markers of disease severity and changes towards normalization under treatment. The Swiss HIV Cohort Study. Clin Exp Immunol (1999) 0.98
Redox and activation status of monocytes from human immunodeficiency virus-infected patients: relationship with viral load. J Virol (1999) 0.97
Naïve and memory CD4+ T cells and T cell activation markers in HIV-1 infected children on HAART. Clin Exp Immunol (2001) 0.96
Assessment of CD8 T cell immune activation markers to monitor response to antiretroviral therapy among HIV-1 infected patients in Côte d'Ivoire. Clin Exp Immunol (2005) 0.96
Phenotype and functionality of CD4+ and CD8+ T cells in the upper reproductive tract of healthy premenopausal women. Am J Reprod Immunol (2013) 0.96
Preserved immune system in long-term asymptomatic vertically HIV-1 infected children. Clin Exp Immunol (2003) 0.95
Immune activation is associated with increased gut microbial translocation in treatment-naive, HIV-infected children in a resource-limited setting. J Acquir Immune Defic Syndr (2014) 0.94
Shigella infection induces cellular activation of T and B cells and distinct species-related changes in peripheral blood lymphocyte subsets during the course of the disease. Infect Immun (1995) 0.93
Association between discordant immunological response to highly active anti-retroviral therapy, regulatory T cell percentage, immune cell activation and very low-level viraemia in HIV-infected patients. Clin Exp Immunol (2014) 0.92
In vitro influence of Mycoplasma penetrans on activation of peripheral T lymphocytes from healthy donors or human immunodeficiency virus-infected individuals. Infect Immun (1995) 0.91
IL-7 enhancement of antigen-driven activation/expansion of HIV-1-specific cytotoxic T lymphocyte precursors (CTLp). Clin Exp Immunol (1995) 0.89
A single measurement of CD38CD8 cells in HIV+, long-term surviving injecting drug users distinguishes those who will progress to AIDS from those who will remain stable. Clin Exp Immunol (2000) 0.89
Lysis of CD4+ lymphocytes by non-HLA-restricted cytotoxic T lymphocytes from HIV-infected individuals. Clin Exp Immunol (1993) 0.89
Interleukin-2-inducible natural immune (lymphokine-activated killer cell) responses as a functional correlate of progression to AIDS. Clin Diagn Lab Immunol (1994) 0.88
Stimulated proliferative responses in vertically HIV-infected children on HAART correlate with clinical and immunological markers. Clin Exp Immunol (2003) 0.83
Normal range estimation for repeated immunologic measures. Clin Diagn Lab Immunol (1996) 0.83
Association of HIV clinical disease progression with profiles of early immune activation: results from a cluster analysis approach. AIDS (2013) 0.82
Isolation of Exosomes from the Plasma of HIV-1 Positive Individuals. J Vis Exp (2016) 0.82
Timing of lymphocyte activation in neonates infected with human immunodeficiency virus. Clin Diagn Lab Immunol (1997) 0.82
Virus load correlates inversely with the expression of cytotoxic T lymphocyte activation markers in HIV-1-infected/AIDS patients showing MHC-unrestricted CTL-mediated lysis. Clin Exp Immunol (2003) 0.81
Abnormalities in host defense associated with HIV infection. Clin Chest Med (2013) 0.81
Depression in caregivers of demented patients is associated with altered immunity: impaired proliferative capacity, increased CD8+, and a decline in lymphocytes with surface signal transduction molecules (CD38+) and a cytotoxicity marker (CD56+ CD8+). Clin Exp Immunol (1995) 0.81
Interlaboratory variability of CD8 subset measurements by flow cytometry and its applications to multicenter clinical trials. NAID/NICHD Women and Infants Transmission Study Group. Clin Diagn Lab Immunol (1995) 0.80
Peripheral neuropathy in primary HIV infection associates with systemic and central nervous system immune activation. J Acquir Immune Defic Syndr (2014) 0.80
The intensity of immune activation is linked to the level of CCR5 expression in human immunodeficiency virus type 1-infected persons. Immunology (2012) 0.80
Kinetics of lymphokine production in HIV+ patients treated with highly active antiretroviral therapy and interleukin 2. J Clin Immunol (1999) 0.80
CD8 T lymphocyte subset markers and HIV infection. Clin Exp Immunol (1992) 0.79
Increased T-cell activation and Th1 cytokine concentrations prior to the diagnosis of B-cell lymphoma in HIV infected patients. J Clin Immunol (2012) 0.79
Soluble tumour necrosis factor receptors (sTNF-R) and HIV infection: correlation to CD8+ lymphocytes. Clin Exp Immunol (1993) 0.79
Simian Immunodeficiency Virus Infection of Chimpanzees (Pan troglodytes) Shares Features of Both Pathogenic and Non-pathogenic Lentiviral Infections. PLoS Pathog (2015) 0.77
Immune activation and viral replication after vaccination with an influenza A H1N1 2009 vaccine in HIV-infected children receiving antiretroviral therapy. Dis Markers (2013) 0.76
Role of immune activation in CD4+ T-cell depletion in HIV-1 infected Indian patients. Eur J Clin Microbiol Infect Dis (2008) 0.76
Peptide-based identification of functional motifs and their binding partners. J Vis Exp (2013) 0.76
The expansion of CD8 lymphocytes using T cell receptor variable gene products during HIV infection. Clin Exp Immunol (1993) 0.75
Can repeated plasma donation by asymptomatic HIV-infected individuals delay the onset of AIDS? Philos Trans R Soc Lond B Biol Sci (1997) 0.75
OMIP-024: pan-leukocyte immunophenotypic characterization of PBMC subsets in human samples. Cytometry A (2014) 0.75
Hallmarks of HIV-1 pathogenesis are modulated by Nef's Secretion Modification Region. J AIDS Clin Res (2015) 0.75
Chronic fatigue syndrome. Immunological findings vary between populations. BMJ (1994) 0.75
An imbalance of naive and memory/effector subsets and altered expression of CD38 on T lymphocytes in two girls with hyper-IgM syndrome. Clin Exp Immunol (2004) 0.75
Improvements in Immune Function and Activation with 48-Week Darunavir/Ritonavir-Based Therapy: GRACE Substudy. ISRN AIDS (2013) 0.75
Silymarin suppresses basal and stimulus-induced activation, exhaustion, differentiation, and inflammatory markers in primary human immune cells. PLoS One (2017) 0.75
CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science (1986) 9.17
The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med (1990) 6.94
The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group. Ann Intern Med (1990) 5.55
The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group. N Engl J Med (1990) 4.25
Ia determinants on stimulated human T lymphocytes. Occurrence on mitogen- and antigen-activated T cells. J Exp Med (1979) 3.76
T-cell subset alterations in HIV-infected homosexual men: NIAID Multicenter AIDS cohort study. Clin Immunol Immunopathol (1989) 3.00
Sources of variability in repeated T-helper lymphocyte counts from human immunodeficiency virus type 1-infected patients: total lymphocyte count fluctuations and diurnal cycle are important. J Acquir Immune Defic Syndr (1990) 2.84
Peripheral blood Ia-positive T cells. Increases in certain diseases and after immunization. J Exp Med (1980) 2.76
Patterns of T lymphocyte changes with human immunodeficiency virus infection: from seroconversion to the development of AIDS. J Acquir Immune Defic Syndr (1989) 2.65
Quantitative changes in T helper or T suppressor/cytotoxic lymphocyte subsets that distinguish acquired immune deficiency syndrome from other immune subset disorders. Am J Med (1984) 2.60
CD8+ cell anti-HIV activity correlates with the clinical state of the infected individual. J Clin Invest (1991) 2.40
Correlation between immunologic function and clinical subpopulations of patients with the acquired immune deficiency syndrome. Am J Med (1985) 2.18
NIH conference. Immunopathogenic mechanisms in human immunodeficiency virus (HIV) infection. Ann Intern Med (1991) 2.15
CD8+ T cells inhibit HIV replication in naturally infected CD4+ T cells. Evidence for a soluble inhibitor. J Immunol (1990) 2.13
Expression of the human leukocyte adhesion molecule, LAM1. Identity with the TQ1 and Leu-8 differentiation antigens. J Immunol (1990) 2.13
CD4 percentage, CD4 number, and CD4:CD8 ratio in HIV infection: which to choose and how to use. J Acquir Immune Defic Syndr (1989) 2.10
Differential expression of homing-associated adhesion molecules by T cell subsets in man. J Immunol (1990) 2.01
Comparative expression of T9, T10, and Ia antigens on activated human T cell subsets. Hum Immunol (1981) 1.57
Activated lymphocytes during acute Epstein-Barr virus infection. J Immunol (1987) 1.42
Expression of HLA-DR on T lymphocytes following renal transplantation, and association with graft-rejection episodes and cytomegalovirus infection. Transplantation (1984) 1.32
Three-color cytofluorometric analysis of CD8 cell subsets in HIV-1 infection. J Acquir Immune Defic Syndr (1991) 1.31
Establishing optimal lymphocyte gates for immunophenotyping by flow cytometry. Cytometry (1990) 1.29
Involvement of the multilineage CD38 molecule in a unique pathway of cell activation and proliferation. J Immunol (1990) 1.28
Nonrandom development of immunologic abnormalities after infection with human immunodeficiency virus: implications for immunologic classification of the disease. Proc Natl Acad Sci U S A (1987) 1.24
Interrelationships between serologic markers of immune activation and T lymphocyte subsets in HIV infection. J Acquir Immune Defic Syndr (1990) 1.21
Selective alterations in immunoregulatory lymphocyte subsets in early HIV (human T-lymphotropic virus type III/lymphadenopathy-associated virus) infection. J Clin Immunol (1987) 1.12
T lymphocyte subset changes in human immunodeficiency virus infection. J Acquir Immune Defic Syndr (1989) 1.09
Surrogate markers for survival in patients with AIDS and AIDS related complex treated with zidovudine. BMJ (1991) 1.08
T activation marker evaluation in ARC patients treated with AZT. Comparison with CD4+ lymphocyte count in non-progressors and progressors towards AIDS. Clin Exp Immunol (1990) 1.05
Abnormality of Leu 2+7+ cells in acquired immune deficiency syndrome (AIDS), AIDS-related complex, and asymptomatic homosexuals. J Clin Immunol (1986) 1.05
Flow cytometric and morphologic studies of HNK1+ (Leu 7+) lymphocytes in relation to cytomegalovirus carrier status. Clin Exp Immunol (1988) 1.03
Class II molecules of the major histocompatibility complex considered as differentiation markers. Hum Immunol (1986) 1.01
CD4 and CD8 subsets defined by dual-color cytofluorometry which distinguish symptomatic from asymptomatic blood donors seropositive for human immunodeficiency virus. Diagn Clin Immunol (1987) 0.96
Preferential loss of Leu 8-, CD45R, HLA-DR+ CD8 cell subsets during in vitro culture of mononuclear cells from human immunodeficiency virus type I (HIV)-seropositive former blood donors. J Clin Immunol (1989) 0.88
Alterations of functional subsets of T helper and T suppressor cell populations in acquired immunodeficiency syndrome (AIDS) and chronic unexplained lymphadenopathy. J Clin Immunol (1985) 0.83
Evaluation of antibiotic diffusion into cardiac vegetations by quantitative autoradiography. J Infect Dis (1989) 3.09
Mechanisms of regulation of cell-mediated immunity. II. Induction and suppression of delayed-type hypersensitivity to azobenzenearsonate-coupled syngeneic cells. J Immunol (1978) 2.52
Activities of clarithromycin, sulfisoxazole, and rifabutin against Mycobacterium avium complex multiplication within human macrophages. Antimicrob Agents Chemother (1990) 2.46
Age-related changes in human blood lymphocyte subpopulations. J Pediatr (1992) 2.17
Use of a new mouse model of Acinetobacter baumannii pneumonia to evaluate the postantibiotic effect of imipenem. Antimicrob Agents Chemother (1997) 2.09
Mechanisms of regulation of cell-mediated immunity. III. The characterization of azobenzenearsonate-specific suppressor T-cell-derived-suppressor factors. J Exp Med (1979) 1.99
Expression of activation antigens, HLA-DR and CD38, on CD8 lymphocytes during HIV-1 infection. AIDS (1992) 1.94
Activities of sparfloxacin, azithromycin, temafloxacin, and rifapentine compared with that of clarithromycin against multiplication of Mycobacterium avium complex within human macrophages. Antimicrob Agents Chemother (1991) 1.77
Antipneumococcal activity of ciprofloxacin, ofloxacin, and temafloxacin in an experimental mouse pneumonia model at various stages of the disease. J Infect Dis (1991) 1.72
Antigen- and receptor-driven regulatory mechanisms. I. Induction of suppressor T cells with anti-idiotypic antibodies. J Exp Med (1979) 1.62
In vivo efficacy of a new fluoroquinolone, sparfloxacin, against penicillin-susceptible and -resistant and multiresistant strains of Streptococcus pneumoniae in a mouse model of pneumonia. Antimicrob Agents Chemother (1992) 1.61
In vivo efficacy of a broad-spectrum cephalosporin, ceftriaxone, against penicillin-susceptible and -resistant strains of Streptococcus pneumoniae in a mouse pneumonia model. Antimicrob Agents Chemother (1994) 1.50
In vivo activities and penetration of the two components of the streptogramin RP 59500 in cardiac vegetations of experimental endocarditis. Antimicrob Agents Chemother (1994) 1.48
Antigen- and receptor-driven regulatory mechanisms. II. Induction of suppressor T cells with idiotype-coupled syngeneic spleen cells. J Exp Med (1979) 1.42
Tropisetron in the prevention of nausea and vomiting in 131 children receiving cytotoxic chemotherapy. Med Pediatr Oncol (1995) 1.41
Performance evaluation of the FACSCount System: a dedicated system for clinical cellular analysis. Cytometry (1996) 1.40
Validation of the INNO-LIA syphilis kit as a confirmatory assay for Treponema pallidum antibodies. J Clin Microbiol (2000) 1.39
In vivo assessment of antimicrobial agents against Toxoplasma gondii by quantification of parasites in the blood, lungs, and brain of infected mice. Antimicrob Agents Chemother (1990) 1.38
Efficacy of pefloxacin in comparison with erythromycin in the treatment of experimental guinea pig legionellosis. J Antimicrob Chemother (1986) 1.35
Idiotype-specific T cell immunity. I. Generation of effector and suppressor T lymphocytes reactive with myeloma idiotypic determinants. J Immunol (1980) 1.35
Specific antinuclear antibodies are associated with clinical features in systemic lupus erythematosus. Ann Rheum Dis (2004) 1.32
Establishing optimal lymphocyte gates for immunophenotyping by flow cytometry. Cytometry (1990) 1.29
Effect of increased dosages of amoxicillin in treatment of experimental middle ear otitis due to penicillin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother (1993) 1.29
Comparative activity of fluorinated quinolones in acute and subacute Streptococcus pneumoniae pneumonia models: efficacy of temafloxacin. J Antimicrob Chemother (1991) 1.22
Prophylactic and therapeutic activities of azithromycin in a mouse model of pneumococcal pneumonia. Antimicrob Agents Chemother (1991) 1.18
Macrolides and immunity: effects of erythromycin and spiramycin on human mononuclear cell proliferation. J Antimicrob Chemother (1986) 1.17
Mechanisms of regulation of cell-mediated immunity: anti-I-A alloantisera interfere with induction and expression of T-cell-mediated immunity to cell-bound antigen in vivo. Clin Immunol Immunopathol (1980) 1.10
Kinetics of lymphocyte subsets from peripheral blood during a Plasmodium falciparum malaria attack. Clin Exp Immunol (1992) 1.09
Synergistic activity of azithromycin and pyrimethamine or sulfadiazine in acute experimental toxoplasmosis. Antimicrob Agents Chemother (1992) 1.09
Genetic and serological analysis of the expression of crossreactive idiotypic determinants on anti-p-azobenzenarsonate antibodies and p-azobenzenarsonate-specific suppressor T cell factors. Proc Natl Acad Sci U S A (1981) 1.07
Sparfloxacin, ethambutol, and cortisol receptor inhibitor RU-40 555 treatment for disseminated Mycobacterium avium complex infection of normal C57BL/6 mice. Antimicrob Agents Chemother (1992) 1.07
Serological confirmation of Chagas' disease by a recombinant and peptide antigen line immunoassay: INNO-LIA chagas. J Clin Microbiol (2000) 1.06
Activities of WIN-57273, minocycline, clarithromycin, and 14-hydroxy-clarithromycin against Mycobacterium avium complex in human macrophages. Antimicrob Agents Chemother (1992) 1.06
T activation marker evaluation in ARC patients treated with AZT. Comparison with CD4+ lymphocyte count in non-progressors and progressors towards AIDS. Clin Exp Immunol (1990) 1.05
[Relationship between virulence and resistance to antibiotics in pneumococci. Contribution of experimental data obtained in an animal model]. Pathol Biol (Paris) (1991) 1.05
Comparative effects of quinolones on human mononuclear leucocyte functions. J Antimicrob Chemother (1987) 1.04
Activity and local delivery of azithromycin in a mouse model of Haemophilus influenzae lung infection. Antimicrob Agents Chemother (1992) 1.04
Humoral and cell-mediated immune responses to the Plasmodium falciparum antigens PF155/RESA and CS protein: seasonal variations in a population recently reexposed to endemic malaria. Am J Trop Med Hyg (1990) 1.04
CSF phosphorylated tau is a possible marker for discriminating Alzheimer's disease from dementia with Lewy bodies. Phospho-Tau International Study Group. Neurol Sci (2001) 1.03
Ceftriaxone diffusion into cardiac fibrin vegetation. Qualitative and quantitative evaluation by autoradiography. Fundam Clin Pharmacol (1991) 1.03
Differential modulation of cytokine production by macrolides: interleukin-6 production is increased by spiramycin and erythromycin. Antimicrob Agents Chemother (1991) 1.00
Correlation between macrolide lung pharmacokinetics and therapeutic efficacy in a mouse model of pneumococcal pneumonia. J Antimicrob Chemother (1993) 1.00
Pharmacokinetics of four fluoroquinolones in an animal model of infected lung. J Antimicrob Chemother (1991) 0.99
Ocular kinetics of pefloxacin after intramuscular administration in albino and pigmented rabbits. Antimicrob Agents Chemother (1991) 0.98
Presence of rheumatoid factor and antibodies to citrullinated peptides in systemic lupus erythematosus. Ann Rheum Dis (2005) 0.97
[Biotransformation of amiodaquine and prophylaxis of Plasmodium falciparum malaria]. C R Acad Sci III (1985) 0.97
Intraphagocytic penetration of macrolides: in-vivo comparison of erythromycin and spiramycin. J Antimicrob Chemother (1985) 0.97
Cerebrospinal fluid tau and beta-amyloid(1-42) in dementia disorders. Mech Ageing Dev (2001) 0.96
A recombinant peptide antigen line immunoassay optimized for the confirmation of Chagas' disease. Transfusion (1999) 0.96
Anti-Toxoplasma effects of dapsone alone and combined with pyrimethamine. Antimicrob Agents Chemother (1991) 0.96
C-reative protein in the rabbit: isolation, characterization and binding affinity to phosphocholine. Immunochemistry (1977) 0.96
Cytofluorometric analysis of chondrotoxicity of fluoroquinolone antimicrobial agents. Antimicrob Agents Chemother (1994) 0.95
Efficacy of granulocyte colony-stimulating factor and RU-40555 in combination with clarithromycin against Mycobacterium avium complex infection in C57BL/6 mice. Antimicrob Agents Chemother (1993) 0.95
Roxithromycin treatment of mouse chlamydial salpingitis and protective effect on fertility. Antimicrob Agents Chemother (1991) 0.93
Pharmacodynamic activities of ciprofloxacin and sparfloxacin in a murine pneumococcal pneumonia model: relevance for drug efficacy. J Pharmacol Exp Ther (1998) 0.92
Efficacy and ocular penetration of sparfloxacin in experimental streptococcal endophthalmitis. Antimicrob Agents Chemother (1993) 0.92
Primary prophylaxis against common infectious diseases in persons with human immunodeficiency virus infection. Am Rev Respir Dis (1991) 0.92
Arterial blood gases and acid-base status in awake rats. Respir Physiol (1982) 0.92
Efficacy of temafloxacin in experimental Streptococcus adjacens endocarditis and autoradiographic diffusion pattern of [14C]temafloxacin in cardiac vegetations. Antimicrob Agents Chemother (1992) 0.91
3H-spiramycin penetration into fibrin vegetations in an experimental model of streptococcal endocarditis. J Antimicrob Chemother (1988) 0.90
Activities of roxithromycin against Mycobacterium avium infections in human macrophages and C57BL/6 mice. Antimicrob Agents Chemother (1995) 0.89
Effects of fluoroquinolones on cultured articular chondrocytes flow cytometric analysis of free radical production. J Pharmacol Exp Ther (1994) 0.89
Protection of rat from oxygen toxicity by inducers of cytochrome P-450 system. Am Rev Respir Dis (1988) 0.88
Flow cytometric analysis of peripheral blood lymphocytes in ulcerative colitis and Crohn's disease. Gut (1991) 0.88
Influence of the pre-treatment duration of infection on the efficacies of various antibiotic regimens in experimental streptococcal endocarditis. J Antimicrob Chemother (1993) 0.88
Clarithromycin, minocycline, and rifabutin treatments before and after infection of C57BL/6 mice with Mycobacterium avium. Antimicrob Agents Chemother (1993) 0.88
Dextranase enhances antibiotic efficacy in experimental viridans streptococcal endocarditis. Antimicrob Agents Chemother (1994) 0.88
Comparative postantibacterial activities of pefloxacin, ciprofloxacin, and ofloxacin against intracellular multiplication of Legionella pneumophila serogroup 1. Antimicrob Agents Chemother (1990) 0.87
Respiratory and pulmonary alterations in experimental Pneumocystis carinii pneumonia in rats. Bull Eur Physiopathol Respir (1985) 0.87
Endothelial uptake of amino acids, sugars, lipids, and prostaglandins in rat lung. Am J Physiol (1982) 0.87
Two-color immunofluorescence and flow cytometric analysis of peripheral blood lymphocyte subsets in Caucasian and Japanese healthy subjects. Jpn J Med (1992) 0.87
Experimental evaluation of combined prophylaxis against murine pneumocystosis and toxoplasmosis. J Infect Dis (1994) 0.87
Synergistic activity of clarithromycin and minocycline in an animal model of acute experimental toxoplasmosis. Antimicrob Agents Chemother (1992) 0.87
Respiratory and non-respiratory causes of death in the rat exposed to normobaric oxygen. Bull Eur Physiopathol Respir (1982) 0.86
[Protection of the pulmonary toxic effects of normobaric oxygen by inducers of cytochrome P450-linked monooxygenases]. C R Acad Sci III (1986) 0.86
Efficacy of single-dose ceftriaxone in experimental otitis media induced by penicillin- and cephalosporin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother (1996) 0.85
Acid-base status of awake rats after cannulation of aorta and vena cava. Kidney Int (1983) 0.85
Hypothesis. The physiological regulation of immunity: differential regulatory contributions of peripheral and central lymphon compartments. Cell Immunol (1979) 0.85
Hospital-acquired infections in Belgian acute-care hospitals: an estimation of their global impact on mortality, length of stay and healthcare costs. Epidemiol Infect (2011) 0.85
Otogenic meningoencephalitis induced by Streptococcus pneumoniae in gerbils. Arch Otolaryngol Head Neck Surg (1994) 0.85
Protective value of elevated levels of gamma interferon in serum against exoerythrocytic stages of Plasmodium falciparum. J Clin Microbiol (1991) 0.85
Individual and combined activities of clarithromycin and its 14-hydroxy metabolite in a murine model of Haemophilus influenzae infection. J Antimicrob Chemother (1991) 0.85
Diethyldithiocarbamate provides partial protection against pulmonary and lymphoid oxygen toxicity. J Pharmacol Exp Ther (1986) 0.84
Protective effects of ciprofloxacin against type II collagen induced arthritis in rats. J Rheumatol (1992) 0.84
Evaluation of a rabbit model for osteomyelitis by high field, high resolution imaging using the chemical-shift-specific-slice-selection technique. Magn Reson Imaging (1994) 0.84
Serum lipids and apoproteins in students whose parents suffered prematurely from a myocardial infarction. Am Heart J (1986) 0.84
Direct activation of human monocyte-derived macrophages by a bacterial glycoprotein extract inhibits the intracellular multiplication of virulent Legionella pneumophila serogroup 1. Infect Immun (1987) 0.83
The television, school and family smoking prevention/cessation project. IV. Controlling for program success expectancies across experimental and control conditions. Addict Behav (1989) 0.83
Interactions between murine AIDS (MAIDS) and toxoplasmosis in co-infected mice. Clin Exp Immunol (1994) 0.82
Kinetics and tolerability of intravitreal pefloxacin in rabbits. J Antimicrob Chemother (1994) 0.82
Control of acid-base status during hypothermia in man. Respir Physiol (1980) 0.82
Clinical optimization and multicenter validation of antigen-specific cut-off values on the INNO-LIA ANA update for the detection of autoantibodies in connective tissue disorders. Clin Exp Rheumatol (2004) 0.81
The 2007 Belgian national prevalence survey for hospital-acquired infections. J Hosp Infect (2010) 0.81
Efficacy of continuous zidovudine infusion at early stages of retroviral infection in mice. J Acquir Immune Defic Syndr (1992) 0.81
[Metabolic acidosis with hypokalemia during isoproterenol perfusion in dogs]. J Physiol (Paris) (1970) 0.81
Use of normal C57BL/6 mice with established Mycobacterium avium infections as an alternative model for evaluation of antibiotic activity. Antimicrob Agents Chemother (1995) 0.81
Respiratory effects of normobaric oxygen toxicity in awake guinea-pig. Comp Biochem Physiol B (1983) 0.81